# Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

> **NCT07627711** · PHASE1,PHASE2 · RECRUITING · sponsor: **Beijing Biotech** · enrollment: 42 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma (PDAC)
- Unresectable Locally Advanced
- Metastatic Disease

## Interventions

- **BIOLOGICAL:** EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1)
- **BIOLOGICAL:** EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1)
- **DRUG:** Lymphodepleting chemotherapy (Flu/Cy)

## Key facts

- **NCT ID:** NCT07627711
- **Lead sponsor:** Beijing Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-02
- **Primary completion:** 2027-04-14
- **Final completion:** 2028-03-17
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07627711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07627711, "Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07627711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*